Overview
Hemolytic anemia due to glucosephosphate isomerase (GPI) deficiency, also known as glucose-6-phosphate isomerase deficiency or phosphoglucose isomerase (PGI) deficiency, is a rare inherited metabolic disorder affecting red blood cells. GPI is an enzyme in the glycolytic (Embden-Meyerhof) pathway, which is the primary energy-producing pathway in red blood cells. When this enzyme is deficient, red blood cells cannot generate adequate energy (ATP), leading to their premature destruction (hemolysis). GPI deficiency is considered the second most common cause of hereditary nonspherocytic hemolytic anemia among glycolytic enzyme defects, after pyruvate kinase deficiency. Clinical features typically present in the neonatal or infantile period and include chronic hemolytic anemia of variable severity, jaundice (including neonatal hyperbilirubinemia that may require exchange transfusion), splenomegaly, and reticulocytosis. Some patients may experience hemolytic crises triggered by infections or other stressors. In severe cases, hydrops fetalis has been reported. A subset of patients may also exhibit mild neuromuscular manifestations, as GPI also functions as a neurotrophic factor (neuroleukin) outside of red blood cells, though neurological involvement is not a consistent feature. Treatment is primarily supportive. Red blood cell transfusions may be required during severe anemia or hemolytic crises, and folic acid supplementation is commonly recommended to support increased red cell production. Splenectomy has been performed in some patients with severe disease and may reduce transfusion requirements and improve hemoglobin levels, though hemolysis is not completely eliminated. Iron overload from chronic hemolysis and/or transfusions may necessitate iron chelation therapy. There is currently no curative treatment, though management of complications can significantly improve quality of life.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Hemolytic anemia due to glucophosphate isomerase deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hemolytic anemia due to glucophosphate isomerase deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hemolytic anemia due to glucophosphate isomerase deficiency.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hemolytic anemia due to glucophosphate isomerase deficiency.
Community
No community posts yet. Be the first to share your experience with Hemolytic anemia due to glucophosphate isomerase deficiency.
Start the conversation →Latest news about Hemolytic anemia due to glucophosphate isomerase deficiency
No recent news articles for Hemolytic anemia due to glucophosphate isomerase deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hemolytic anemia due to glucophosphate isomerase deficiency
What is Hemolytic anemia due to glucophosphate isomerase deficiency?
Hemolytic anemia due to glucosephosphate isomerase (GPI) deficiency, also known as glucose-6-phosphate isomerase deficiency or phosphoglucose isomerase (PGI) deficiency, is a rare inherited metabolic disorder affecting red blood cells. GPI is an enzyme in the glycolytic (Embden-Meyerhof) pathway, which is the primary energy-producing pathway in red blood cells. When this enzyme is deficient, red blood cells cannot generate adequate energy (ATP), leading to their premature destruction (hemolysis). GPI deficiency is considered the second most common cause of hereditary nonspherocytic hemolytic a
How is Hemolytic anemia due to glucophosphate isomerase deficiency inherited?
Hemolytic anemia due to glucophosphate isomerase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hemolytic anemia due to glucophosphate isomerase deficiency typically begin?
Typical onset of Hemolytic anemia due to glucophosphate isomerase deficiency is neonatal. Age of onset can vary across affected individuals.